Journal of Child and Adolescent Psychopharmacology

Article	Citations
Acknowledgment of Reviewers 2023	30
Letter to the Editor: Skin-Testing for Clones—Pediatric Obsessive Compulsive Disorder with Misidentification Syndrome	27
Pharmacological Treatment of Tourette Disorder in Children	25
Letter: Mirtazapine-Associated Hyperkinetic Movements in a 17-Year-Old with Autism Spectrum Disorder and Chronic Catatonia: A Case Report	24
Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis	21
Pharmacogenetics in Child and Adolescent Psychiatry: Background and Evidence-Based Clinical Applications	19
Reducing Psychotropic Medication Use in Foster-Care Children with a Personalized Medication Review	19
Navigating Pharmacological Treatment in an Adolescent with New Onset Psychosis: Clinical, Pharmacological, and Cultural Challenges	17
Description, Implementation, and Efficacy of the Comprehensive Behavioral Intervention for Tics as First-Line Treatment for Tourette and Other Tic Disorders	17
A Randomized, Double-Blind, Controlled Trial of Lithium Versus Quetiapine for the Treatment of Acute Mania in Youth with Early Course Bipolar Disorder	16
Serotonin Toxicity in Children and Adolescents: A Systematic Review and Meta-Analysis of Cases	16
From the Editor-in-Chief's Desk: Reflecting on Our Past and Future	16
Monitoring of Adverse Drug Reaction-Related Parameters in Children, Youth, and Young Adults Prescribed Antipsychotic Drugs by General Practitioners	15
A Double-Blind Placebo-Controlled Pilot Study of Topiramate in Manic Adolescents Treated with Olanzapine	13
From the Editor's Desk: Progress and Challenges for Psychiatric Phenotypes in Youth	13
Incidence of Neuroleptic Malignant Syndrome During Antipsychotic Treatment in Children and Youth: A National Cohort Study	13
Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for The Evaluation of Safety (SPRITES)	13
Response to Plöderl et al. re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder”	13
A Mobile Application Adjunct to Augment Cognitive–Behavioral Group Therapy for Adolescents with Social Anxiety: Feasibility and Acceptability Results from the Wiring Adolescents with Social Anxiety vi	12
From the Editor-in-Chief’s Desk: Long-Acting Injectable Antipsychotics	12
Pharmacological Interventions for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Tourette Disorder: A Systematic Review and Network Meta-Analysis	11
Psychotropic Medication Prescribing: Youth in Foster Care Compared with Other Medicaid Enrollees	11
Short-Term Vision-Related Ocular Side Effects of Treatment with Dexmethylphenidate for Attention-Deficit/Hyperactivity Disorder	10
Catatonia in a 16-Year-Old	10
Letter to the Editor: Olanzapine Treatment and Polyuria-Polydipsia in Two Children with Autism Spectrum Disorder	10

Letter to the Editor: Transition to In-Person School After Remote Learning—Mental Health Concerns in Youth with Developmental Disabilities	10
Reported Side or Adverse Effects Associated with Medication Nonadherence Among Adolescents and Young Adults with Attention-Deficit/Hyperactivity Disorder	10
Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor	10
Letter: Integrating Insights on Ketamine Efficacy and the Risk for Polydrug Use in Adolescents with Depression	10
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study	9
Combined Topiramate and Metformin Pharmacotherapy for Second-Generation Antipsychotic-Induced Weight Gain in Pediatric Bipolar Disorder and Aggression	9
Determining Clinically Meaningful Improvement in Children and Adolescents with Tourette Syndrome Receiving Pharmacotherapy	9
Association of Coexisting Conditions, Attention-Deficit/Hyperactivity Disorder Medication Choice, and Likelihood of Improvement in Preschool-Age Children: A Developmental Behavioral Pediatrics Researc	8
Letter to the Editor: Suicide Risk Screening Practices in Youth with Developmental Disabilities	8
Ketamine and Transcranial Magnetic Stimulation in an Adolescent with Treatment-Resistant Depression	8
From the Editor-in-Chief’s Desk: Maximizing Adherence, Digital Platforms, and Early Response for Precision Pediatric Psychopharmacology	8
The Curious Case of Therapist Self-Disclosure During Pharmacotherapy Visits in an Autism Center	8
Letter to the Editor: Chlorpromazine-Induced Skin Pigmentation in a Pediatric Patient	8
Changes in Psychiatric Medication Use During the COVID-19 Pandemic in a Pediatric Long-Term Care Facility	7
Psychiatric Polygenic Risk Scores and Week-by-Week Symptomatic Status in Youth with Bipolar Disorder: An Exploratory Study	7
Can Neurocognitive Outcomes Assist Measurement-Based Care for Children with Attention-Deficit/Hyperactivity Disorder? A Systematic Review and Meta-Analyses of the Relationships Among the Changes in Ne	7
Pediatric Neuropsychiatric Syndromes: Updates on COVID-19 Infection and Vaccination	7
Letter to the Editor: The Impact of the COVID-19 Pandemic on the Mental Health of Youth with Developmental Disabilities	7
A Counting Stroop Functional Magnetic Resonance Imaging Study on the Effects of ORADUR-Methylphenidate in Drug-Naive Children with Attention-Deficit/Hyperactivity Disorder	7
Vascular Endothelial Growth Factor Polymorphism rs699947 Is Associated with Neurostructural Phenotypes in Youth with Bipolar Disorder	6
Fluoxetine-Induced Serum Sickness-Like Reaction in an Adolescent with Obsessive Compulsive Disorder and Diabetes	6
Correction to: A Predictive Biomarker Model Using Quantitative Electroencephalography in Adolescent Major Depressive Disorder, by McVoy, et al. J Child Adolesc Psychopharmacol 2022;32(9)	6
The Safety and Clinical Effects of Amisulpride in Children and Adolescents with Psychiatric Disorders: A Case Series	6
Relative Age and the Use of Second-Generation Antipsychotics from 7 to 17 Years of Age: A Population-Based Register Study	6
From the Editor-in-Chief's Desk	6
A Preclinical Study of Standard Versus Accelerated Transcranial Magnetic Stimulation for Depression in Adolescents	6
Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia	6
Pain in Tourette Syndrome: A Comprehensive Review	6
From the Editor-in-Chief's Desk	6
Rational Psychopharmacological and Psychotherapeutic Treatment of a 14-Year-Old Female with Functional Neurological Symptoms Disorder and Depression	6
Response to Chadi A. Calarge re: “Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)”	6
Long-Term Improvement and Safety of Aripiprazole for Irritability and Adaptive Function in Asian Children and Adolescents with Autistic Disorder: A 52-Week, Multinational, Multicenter, Open-Label Stud	5
Long-Acting Injectable Antipsychotics in Adolescents with Bipolar Disorder	5
Clonazepam Treatment of Adolescent Catatonia in A Setting of Lorazepam-Related Hypotension	5
Letter to the Editor: Aripiprazole-Induced Hypersexuality in an Autistic Child	5
Stimulant Patterns, Alone or with Other Psychotropic Classes, in Medicaid-Insured Youth Continuously Enrolled for 3–8 Years	5
Examining Whether Genetic Variants Moderate the Skeletal Effects of Selective Serotonin Reuptake Inhibitors in Older Adolescents and Young Adults	5
Bowel and Bladder Dysfunction Is Associated with Psychiatric Comorbidities and Functional Impairment in Pediatric Obsessive-Compulsive Disorder	5
Correction to: A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder, by Strawn et al. J Child Adolesc Psychopha	5
Multivariable Prediction Modeling of Antidepressant Initiation in Unipolar Depressed Adolescents: A Secondary Analysis of the IMPACT Trial	5
Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for Journal of Child and Adolescent Psychopharmacology	5
Association Between Single-Dose and Longer Term Clinical Response to Stimulants in Attention-Deficit/Hyperactivity Disorder: A Systematic Review of Randomized Controlled Trials	5
Letter: Collaborating with Applied Behavior Analysis Teams to Optimize Telehealth Pharmacologic Management of Catatonia in Nonverbal Youth with Autism Spectrum Disorder	5
From the Editor-in-Chief’s Desk: Gratitude for Mentors and Colleagues	5
Factors Associated with Symptom Persistence in PANS: Part II—Presenting Features, Medical Comorbidities, and IVIG Treatment History	5
Evaluation of the Psychometric Properties of the Persian Version of Children's Depression Inventory in Iranian Adolescents	4
Results from a Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Crossover Trial of Lovastatin or Minocycline in Fragile X Syndrome	4
Trajectories and Predictors for the Development of Clinically Significant Weight Gain in Children and Adolescents Prescribed Second-Generation Antipsychotics	4
Efficacy of Preventing Relapse Evaluated by a Multicenter Randomized Double-Blind Placebo-Controlled Withdrawal Study of Escitalopram in Japanese Adolescents with Major Depressive Disorder	4
Neurocognitive Outcomes from Memantine: A Pilot, Double-Blind, Placebo-Controlled Trial in Children with Autism Spectrum Disorder	4

Prevalence and Factors Affecting the Use of Antipsychotics and Antipsychotic Polypharmacy in a Child and Adolescent Psychiatry Inpatient Service	4
From the Editor-in-Chief’s Desk: Special Issue on the Psychopharmacology of Neurodevelopmental Disorders	4
Correction to: The Importance of Second-Generation Antipsychotic-Related Weight Gain and Adherence Barriers in Youth with Bipolar Disorders: Patient, Parent, and Provider Perspectives, by Klein	4
Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-	4
Clinicians' Adherence to Guidelines When Initiating Methylphenidate Treatment	4
Clinical Use of Clozapine Serum Level and Management of Adverse Effects in an Adolescent with Difficult to Treat Schizophrenia	4
From the Editor-in-Chief's Desk: Advances in Patient-Centered Treatment for Attention-Deficit/Hyperactivity Disorder	4
A National Pediatric Telepsychiatry Curriculum for Graduate Medical Education and Continuing Medical Education	4
Electronically Monitored Antidepressant Adherence in Adolescents with Anxiety Disorders: A Pilot Study	4
A Scoping Review of the Intersectionality of Autism and Intellectual and Developmental Disability with Social Inequity on Diagnosis and Treatment of Youth	4
Screening for Depression in Adolescents with Developmental Disabilities: Brief Report	4
Comparing Symptoms of Major Depression in Youth with Confirmed Versus Suspected Bipolar Disorder	4
A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder	4
Adherence to Clinical Guidelines for Dose Finding and Monitoring Methylphenidate Use: A Medical Record Audit in Child and Adolescent Mental Health Care and Pediatric Settings	4
Inflammatory Markers Profile in Older Adolescents During Treatment with Selective Serotonin Reuptake Inhibitors	3
From the Editor-in-Chief's Desk	3
From the Editor-in-Chief's Desk	3
Risk of Obesity Among Children Prescribed Atypical Antipsychotics for Six Months or More	3
A Discrepancy in the Reports on Life Events Between Parents and Their Depressed Children Is Associated with Lower Responsiveness to SSRI Treatment	3
Letter: Food and Drug Administration Clearance of Transcranial Magnetic Stimulation for Adolescent Depression in the Absence of Data Supporting Efficacy	3
Letter: Extended-Release Lorazepam as a Safe and Effective Option for Treating Catatonia in an Individual with Down Syndrome	3
Viloxazine Extended-Release Administered With Psychostimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Phase 4, Open-Label Trial	3
Letter to the Editor: Rapid Clozapine Concentration Increase Following Augmentation with Low-Dose Fluvoxamine in 12-Year-Old with Childhood Onset Schizophrenia	3
Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate	3
Relative Age Effect on Problematic Alcohol Use in Adolescents	3
A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder	3
Prevalence and Correlates of Eating Disorder Symptoms in Adolescents with Bipolar I Disorder	3
From the Editor-in-Chief's Desk	3
Longitudinal Patterns of Community-Based Treatment Utilization Among Ethnically and Racially Diverse Adolescents with Attention-Deficit/Hyperactivity Disorder	3
The Efficacy and Cognitive Effects of Acute Course Electroconvulsive Therapy Are Equal in Adolescents, Transitional Age Youth, and Young Adults	3
26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Most Recent Episode Manic)	3
Pharmacogenetics and Oxcarbazepine in Children and Adolescents: Beyond HLA-B*15:02	3
Comorbidities in School-Age Children and Adolescents with Autism in an Ethnically Diverse Population: Brief Report	3
From the Editor-in-Chief's Desk	3
Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study	3
The Psychosocial Environment as Therapeutic Context: Family-Centered Approaches to Adolescent Psychedelic Research	3
From the Editor-in-Chief's Desk	3
Letter: Seventeen-Year-Old Develops Neuroleptic Malignant Syndrome after Brief Low-Dose Exposure to Aripiprazole: A Case Report	3
From the Editor-in-Chief's Desk	3
A Meta-Analysis of Antipsychotic-Induced Hypo- and Hyperprolactinemia in Children and Adolescents	3
A Predictive Biomarker Model Using Quantitative Electroencephalography in Adolescent Major Depressive Disorder	3
Stimulants Concomitant with Other Psychotropic Classes: A Competing Risk Analysis in Medicaid-Insured Youth	3
A Short-Term Group Telehealth Cognitive Behavioral Therapy Intervention for Youth with Autism and Anxiety: A Pilot Study	2
Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies	2
Vineland-3 Growth Scale Values: Psychometric Properties for Clinical Trial Readiness in SCN2A	2
Psychotropic Medication Prescription Patterns in Down Syndrome in a Large Pediatric Specialty Clinic	2
Investigating Predictors of Clozapine Response in Adolescents with Schizophrenia and Schizoaffective Disorder	2
Rosalind Franklin Society Proudly Announces the 2024 Award Recipient for Journal of Child and Adolescent Psychopharmacology	2
Predictors and Moderators of Treatment Outcomes for Anxious Children Randomized to Computer-Assisted Cognitive Behavioral Therapy or Standard Community Care	2
Switch to Lisdexamfetamine in the Treatment of Attention-Deficit Disorder at a Psychiatric Outpatient Clinic for School-Aged Children: A Danish Cohort Study	2
Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality	2
Comparison of Psychiatric Readmission Rates for Child and Adolescent Patients on Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics: A Mirror Study	2
Letter: Exploring the Relationship Between Smartphone Addiction, Psychological Distress, Stress, and Self-Esteem Among Moroccan High School Students: A Regression Equation Modeling Study	2
Clozapine Treatment for Aggressive Behaviors in Youths with Neurodevelopmental Disorders	2
High-Dose Benzodiazepines in Treatment of Malignant Catatonia in an Adolescent: Lorazepam, Clonazepam, and Differing Efficacy	2
Cost-Effectiveness and Cost Utility of Treatment of Attention-Deficit/Hyperactivity Disorder: A Systematic Review	2
Preliminary Observations of Resting-State Magnetoencephalography in Nonmedicated Children with Obsessive-Compulsive Disorder	2
The Mental Health Toll of the COVID-19 Pandemic on Adolescents Receiving Inpatient Psychiatric Treatment	2
From the Editor-in-Chief's Desk	2
Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication Study	2
Examining Antidepressant Side Effect Burden in Youth: The FIBSER-C Scale in the Texas Youth Depression and Suicide Research Network Study	2
Guanfacine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Down Syndrome: A Retrospective Chart Review	2
Understanding and Managing New Onset Homicidal Ideation in an Adolescent with Depression	2
Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression	2
Long-Acting Injectable Antipsychotic Medication Use in Youth: A Systematic Review of the Literature Along with MedWatch Safety Data and Prescriber Attitudes	2
Suicide, Stimulants, and Selective Serotonin Reuptake Inhibitors: A Retrospective Chart Review	2
Pediatric Psychotropic Polypharmacy: An Evaluation of the Correlates and Prevalence Across Assessment Cycles in the National Health and Nutrition Examination Survey	2
Letter: Paradoxical Sedation on Methylphenidate in a Child with Attention-Deficit/Hyperactivity Disorder	2
Exploring Risk Factors for Adverse Reactions in Children with an Acute Psychotic Episode Using the Global Trigger Tool: Does Age Matter?	2
From the Editor-in-Chief's Desk	2
National Trends in Pediatric Obsessive compulsive disorder Management: Insights from a Retrospective Cohort Study	2
Diagnosis of Autism in School Age and Adolescence in an Ethnically Diverse Population	2
Growth Trajectories in Stimulant Treated Children and Adolescents: A Qualitative Review of the Literature from Comprehensive Datasets and Registries	2
Treatment of Adolescent Depression: Comparison of Psychiatric and Pediatric Settings at an Academic Medical Center Using the VitalSign6 Application	2
High-Frequency Utilization of the Outpatient Messaging System in a Specialized Outpatient Catatonia Clinic for Individuals with Autism Spectrum Disorder	2
Letter to the Editor: Antidepressant and Antisuicidal Effects of Esketamine in Adolescents with Major Depressive Disorder and Suicidal Ideation: A Case Series	2
Medication Prescribing Patterns at a Youth Mental Health Service: A Single Center Retrospective Cross-sectional Study	2
Short- and Long-Term Outcomes of Suboptimal Medication Adherence in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Systematic Literature Review	2
Not Too Rare to Matter: The Incidence of Neuroleptic Malignant Syndrome in Children and Adolescents Treated with Antipsychotics	2
Letter to the Editor: Acute Hypertriglyceridemia in an Infant Treated with Quetiapine for Pediatric Delirium	2

Children's Relative Age and Medicine Treatment for Attention-Deficit/Hyperactivity Disorder Across Australian Jurisdictions with Different School Enrolment Policies	2
Re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder” by Strawn et al.—Concerning Harm–Benefit Ratio in a Recent Tria	2
Letter to the Editor: Edible Cannabis Use and Acute Psychotic Episode in an Adolescent	2
The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression	2
Letter: Agitation Management in a 5-Year-Old Boy with X Chromosome-Linked Monoamine Oxidase-A and Monoamine Oxidase-B Deficiency	2
Rett Syndrome Behaviour Questionnaire: Variability of Scores and Related Factors	2
Letter to the Editor: Delayed Fibrosis and Late Course Magnetic Resonance Imaging Findings in Clozapine-Induced Myocarditis in an Adolescent	2
Comparison of Fidgeting in Adolescents with Attention-Deficit/Hyperactivity Disorder Between Before and After Stimulant Medication Intake	2
Letter to the Editor: A Positive Tetrahydrocannabinol on Urine Screen After Cannabidiol Oil Use in an Adolescent	1
Co-Occurring Anxiety in Youth with Tic Disorders: A Review	1
Home-Based Telemental Health: A Proposed Privacy and Safety Protocol and Tool	1
Seclusion-Induced Psychosis in an Adolescent Boy	1
Clozapine and Constipation: Considerations in an Obese Adolescent Girl	1
Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinic	1
From the Editor-in-Chief’s Desk: Harnessing Pharmacoepidemiology to Provide a Brighter Future for Children with Psychiatric Disorders	1
Cognitive, Family, and Quality-of-Life Characteristics of Youth with Depression Associated with Bipolar Disorder	1
Efficacy and Safety of Duloxetine in Children and Adolescents with Major Depressive Disorder in Japan: A Randomized Double-Blind Placebo-Controlled Clinical Trial Followed by an Open-Label Long-Term E	1
Difficult-to-Treat Aggression in a Child with Autism Spectrum Disorder: Did We Miss Something? Bipolar Disorder As a Comorbid Psychiatric Condition in Autism Spectrum Disorder	1
Psychotropic Drug Treatment Patterns in Persons with Fragile X Syndrome	1
Impact of Pharmacogenomics on Pediatric Psychotropic Medication Prescribing in an Ambulatory Care Setting	1
Initiation of Aripiprazole Lauroxil Long-Acting Injectable in Adolescents During Hospitalization: A Case Series	1
Efficacy and Safety of Dextroamphetamine Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results from a Pivotal Phase 2 Study	1
High Probability of Gene-Drug Interactions Associated with Medication Side Effects in Adolescent Depression: Results from a Randomized Controlled Trial of Pharmacogenetic Testing	1
Pharmacotherapy May Attenuate the Risk of Child Abuse in Attention-Deficit/Hyperactivity Disorder from the Real-World Evidence	1
From the Editor-in-Chief’s Desk: Advancing Evidence-Based Treatments for Disruptive Mood Dysregulation Disorder	1
Acknowledgment of Reviewers 2024	1
From the Editor-in-Chief’s Desk: Psychedelic Therapeutics—Something Old and Something New	1
Re: “Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for The Evaluation of Safety (SPRITES)” by Kolitsopoulos et al.	1
Association of Lithium and Second-Generation Antipsychotics with Neurocognition in Youth with Bipolar Disorder	1
Clozapine for Management of Childhood and Adolescent-Onset Schizophrenia: A Systematic Review and Meta-Analysis	1
From the Editor-in-Chief’s Desk: Keeping Our Eyes on The Ball and a Call for Discontinuation Research	1
Characteristic Similarities of Irritability Between Autism and Disruptive Mood Dysregulation Disorder	1
Letter: Can Epileptic Seizures Explain Hyperactive Catatonia in Patients with Autism and Intellectual Disability?	1
The Impact of Development on Antidepressant and Placebo Response in Anxiety Disorders: A Bayesian Hierarchical Meta-Analytic Examination of Randomized Controlled Trials in Children, Adolescents, and A	1
An Investigation of Diversity in Childhood and Adolescent Antidepressant Studies: A Systematic Review	1
From the Editor-in-Chief's Desk	1
Caregiver Burden, Stress, and Relationship Cohesion Among Self-Identified Caregivers of Children with Pediatric Acute-Onset Neuropsychiatric Syndrome	1
Adherence Rates and Barriers to Second-Generation Antipsychotic Medication Use in Youth with Bipolar Spectrum Disorders Who Have Overweight/Obesity	1
SPTAN1—Results of a Caregiver Survey	1
Response: Can Epileptic Seizures Explain Hyperactive Catatonia in Patients with Autism and Intellectual Disability?	1
From the Editor-in-Chief’s Desk: Navigating Flawed Dogma in Child and Adolescent Psychopharmacology	1
Association Between Abnormal Metabolic Parameters and Receiving Subsequent Interventions in Children and Adolescents Initiating Second-Generation Antipsychotics	1
Executive Functioning in Pediatric Anxiety and Its Relationship to Selective Serotonin Reuptake Inhibitor Treatment Response: A Double-Blind, Placebo-Controlled Trial	1
The Aberrant Behavior Checklist for Fragile X Syndrome: A Qualitative Clinician Evaluation of Content Validity	1
Evaluation of the Safer Use of Antipsychotics in Youth Study on Population Level Antipsychotic Initiation: An Interrupted Time Series Analysis	1
Probing the Neurodynamic Mechanisms of Cognitive Flexibility in Depressed Individuals with Autism Spectrum Disorder	1
Letter: A Rare Case of Dose-Dependent Priapism in a Child with Autism Treated with Aripiprazole and Risperidone	1
From the Editors Desk: From Pediatric Infection Triggered Autoimmune Neuropsychiatric Disorders to Long COVID—Progress, Quandaries, and Parallels	1
Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day	1
Selective Serotonin Reuptake Inhibitors and Hydroxyzine in the Treatment of Avoidant/Restrictive Food Intake Disorder in Children and Adolescents: Rationale and Evidence	1
From the Editor-in-Chief's Desk	1
Predictors of Placebo Response in the Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors	1
Psychometric Properties of the PANS 31-Item Symptom Rating Scale	1
The Effects of Methylphenidate Treatment on Bullying Perpetration and Victimization in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder	1
Comparative Efficacy of Omega-3 Fatty Acid with Other Interventions for Depression in Children and Adolescents: A Systematic Review and Network Meta-Analysis	1
A 16-Year-Old Male with Autism Spectrum Disorder, Psychosis, and Refusal to Accept Any Oral Medication: A Case Report and Use of Long-Acting Injectable Aripiprazole Lauroxil	1
Current Utilization of Bupropion Treatment in Children, Young Adults, and Adults in the United States	1
Effect of a Multilayer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Fixed-Dose, Placebo-Co	1
C-Reactive Protein Does Not Predict Future Depression Onset in Adolescents: Preliminary Findings from a Longitudinal Study	1
Reliability and Validity of the Bipolar Prodrome Symptom Interview and Scale-Full Prospective in Its Turkish Translation	1
Sertraline Pediatric Registry for the Evaluation of Safety: Design and Clinical Characteristics of Pediatric Patients Prescribed Sertraline	1
Letter to the Editor: Cannabidiol Treatment—Is There an Effect on Cognitive Functioning, Quality of Life, and Behavior? A Case Report	1
Myths of Randomized Controlled Trial Analysis in Pediatric Psychopharmacology	1
Citalopram Did Not Significantly Improve Anxiety in Children with Autism Spectrum Disorder Undergoing Treatment for Core Symptoms: Secondary Analysis of a Trial to Reduce Repetitive Behaviors	1
Metabolic Monitoring for Children and Adolescents Prescribed Second-Generation Antipsychotics: A Qualitative Study with Child Psychiatrists	1
A Retrospective Examination of the Impact of Pharmacotherapy on Parent–Child Interaction Therapy	1
Psychotropic Prescriptions During the COVID-19 Pandemic Among U.S. Children and Adolescents Receiving Mental Health Services	1
Guanfacine for the Treatment of Attention-Deficit Hyperactivity Disorder: An Updated Systematic Review and Meta-Analysis	1